NIH Funding Cuts Threaten Clinical Trials, Patient Care

A wave of funding cuts at the National Institutes of Health (NIH) is disrupting vital medical research, jeopardizing clinical trials, and potentially delaying access to life-saving treatments for millions of Americans. A recent study published in JAMA Internal Medicine reveals that approximately 3.5% of NIH-funded clinical trials – impacting over 74,000 participants – have been affected by grant terminations, raising serious concerns about the future of medical innovation and patient care.

The Impact of the “One Big Beautiful Bill Act”

The current crisis isn’t solely attributable to NIH cuts. The passage of the “One Big Beautiful Bill Act” this summer, which is projected to slash over $1 trillion from health programs over the next decade, is exacerbating the problem. The legislation is expected to leave more than 10 million Americans without health insurance, with an additional 5 million losing coverage as Affordable Care Act (ACA) subsidies expire in 2025. These coverage losses are predicted to increase uncompensated care by as much as $278 billion, placing immense strain on already-fragile healthcare systems.

“We’re looking at a perfect storm,” explains Curtis E. Haas, PharmD, FCCP, chief pharmacy officer for the University of Rochester Medical Center in New York. “The funding cuts, combined with increased uninsurance rates, will disproportionately impact Medicaid expansion states, rural communities, and underserved urban populations. We’re likely to see rural hospitals closing at an alarming rate.”

Trials Disrupted, Patients at Risk

The study in JAMA Internal Medicine analyzed NIH-funded interventional clinical trials between February and August 2025. Researchers found that trials with higher anticipated enrollment numbers were more likely to be affected by funding cuts. Critically, a significant number of trials – 74,311 individuals – were actively enrolling participants when funding was terminated, leaving patients in a precarious position.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, assistant professor at the University of California San Diego, emphasizes the human cost of these disruptions. “For many patients, clinical trials represent their last hope. Discontinuing a trial can mean losing access to potentially life-saving treatment, leading to mental distress, familial impacts, and, in the most severe cases, mortality.”

Trials conducted outside the United States were particularly vulnerable, with a 5.8% termination rate compared to 3.4% for US-based trials (P=0.009). Regional disparities within the US were also significant, with termination rates ranging from 6.3% in the Northeast to 0% for multi-regional trials.

The Importance of Randomized Controlled Trials

The disruption to clinical trials is particularly concerning because of the crucial role these studies play in medical advancement. The Centers for Disease Control and Prevention highlights the importance of rigorous research in informing public health policy and improving health outcomes. Randomized controlled trials (RCTs) are considered the “gold standard” for medical research, minimizing bias and allowing researchers to establish cause-and-effect relationships.

“RCTs are highly trustworthy,” Abdul-Mutakabbir explains. “Without them, we’re forced to rely on observational studies, which are more susceptible to bias and may not accurately reflect the true impact of a treatment.” The shift away from RCTs could slow the development of new therapies and potentially lead to the adoption of less effective treatments.

Pharmacists: A Critical Safety Net

Amidst this uncertainty, pharmacists are emerging as a vital resource for patients navigating the fallout from disrupted clinical trials. They are often the first point of contact for patients who suddenly find themselves without access to trial medications. Pharmacists can counsel patients on alternative therapies, review medication regimens to prevent gaps in care, and collaborate with prescribers to ensure a smooth transition to evidence-based alternatives.

“Pharmacists are crucial advocates,” Abdul-Mutakabbir adds. “They can identify vulnerable patients and connect them with financial assistance, community resources, and continued care options.” Furthermore, pharmacists play a key role in promoting vaccine uptake and preventing the spread of infectious diseases, particularly important given the recent decline in vaccination rates. According to the World Health Organization, vaccines prevent an estimated 2-3 million deaths each year.

Looking Ahead: A Call for Investment

The study authors emphasize the need for ongoing monitoring of clinical trials affected by NIH grant terminations to assess the long-term consequences. The current situation underscores the critical importance of sustained investment in medical research and accessible healthcare. Without it, the progress made in combating disease and improving public health is at risk. For more information on navigating healthcare changes, explore resources available on worldys.news/health.

The future of medical innovation, and the health of millions, hangs in the balance.